Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Beats Expectations By $1.41 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its earnings results on Monday. The biotechnology company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $1.41, FiscalAI reports.

Oramed Pharmaceuticals Stock Performance

NASDAQ:ORMP traded down $0.10 during trading hours on Monday, reaching $4.20. The company’s stock had a trading volume of 167,508 shares, compared to its average volume of 231,258. The firm has a market capitalization of $174.72 million, a price-to-earnings ratio of 1.62 and a beta of 1.22. The firm has a 50-day simple moving average of $4.12 and a 200-day simple moving average of $3.81. Oramed Pharmaceuticals has a 1 year low of $1.98 and a 1 year high of $5.19.

Insider Transactions at Oramed Pharmaceuticals

In related news, CFO Avraham Gabay sold 73,360 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the sale, the chief financial officer directly owned 671,785 shares in the company, valued at $3,029,750.35. This represents a 9.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Joshua Hexter sold 137,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total value of $611,020.00. Following the transaction, the chief operating officer owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. The trade was a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in Oramed Pharmaceuticals in the fourth quarter worth $738,000. HRT Financial LP purchased a new position in Oramed Pharmaceuticals during the 4th quarter valued at $131,000. Quadrature Capital Ltd bought a new position in Oramed Pharmaceuticals in the 4th quarter worth $119,000. Squarepoint Ops LLC raised its holdings in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Oramed Pharmaceuticals by 31.2% in the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 18,600 shares during the period. Institutional investors own 12.73% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.